{"product_id":"the-molecular-biology-of-cancer-isbn-9781118008812","title":"The Molecular Biology of Cancer","description":"\u003cp\u003e\u003cb\u003eThe Molecular Biology of Cancer, Stella Pelengaris \u0026amp; Michael Khan\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eThis capturing, comprehensive text, extensively revised and updated for its second edition, provides a detailed overview of the molecular mechanisms underpinning the development of cancer and its treatment.\u003c\/p\u003e \u003cp\u003e “Bench to Bedside”: A key strength of this book that sets it apart from general cancer biology references is the interweaving of all aspects of cancer biology from the causes, development and diagnosis through to the treatment and care of cancer patients – essential for providing a broader view of cancer and its impact.\u003c\/p\u003e \u003cp\u003eThe highly readable presentation of a complex field, written by an international panel of researchers, specialists and practitioners, would provide an excellent text for graduate and undergraduate courses in the biology of cancer, medical students and qualified practitioners in the field preparing for higher exams, and for researchers and teachers in the field.\u003c\/p\u003e \u003cp\u003eFor the teaching of cancer biology, special features have been included to facilitate this use: bullet points at the beginning of each chapter explaining key concepts and controversial areas; each chapter builds on concepts learned in previous chapters, with a list of key outstanding questions remaining in the field, suggestions for further reading, and questions for student review. All chapters contain text boxes that provide additional and relevant information.\u003c\/p\u003e \u003cp\u003eKey highlights are listed below:\u003c\/p\u003e \u003cul\u003e \u003cli\u003eAn overview of the cancer cell and important new concepts.\u003c\/li\u003e \u003cli\u003eSelected human cancers: lung, breast, colorectal, prostate, renal, skin, cervix, and hematological malignancies.\u003c\/li\u003e \u003cli\u003eKey cellular processes in cancer biology including (a) traditionally important areas such as cell cycle control, growth regulation, oncogenes and tumour suppressors apoptosis, as well as (b) more highly topical areas of apoptosis, telomeres, DNA damage and repair, cell adhesion, angiogenesis, immunity, epigenetics, and the proteasome.\u003c\/li\u003e \u003cli\u003eClinical oncology: In-depth coverage of important concepts such as screening, risk of cancer and prevention, diagnoses, managing cancer patients from start to palliative care and end-of-life pathways.\u003c\/li\u003e \u003cli\u003eChapters highlighting the direct links between cancer research and clinical applications.\u003c\/li\u003e \u003cli\u003eNew coverage on how cancer drugs are actually used in specific cancer patients, and how therapies are developed and tested.\u003c\/li\u003e \u003cli\u003eSystems Biology and cutting edge research areas covered such as RNA interference (RNAi).\u003c\/li\u003e \u003cli\u003eEach chapter includes key points, chapter summaries, text boxes, and topical references for added comprehension and review.\u003c\/li\u003e \u003cli\u003eQuotations have been used in each chapter to introduce basic concepts in an entertaining way.\u003c\/li\u003e \u003cli\u003eSupported by a dedicated website at http:\/\/www.blackwellpublishing.com\/pelengaris\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eWe should list the great reviews we got for first edition which are on the back of the 2nd edition:\u003c\/p\u003e \u003cp\u003e“A capturing, comprehensive, clearly written and absolutely accurate introduction into cancer biology…..This book deserves great praise for the readable presentation of this complex field….the true synthesis of bench and bedside approaches is marvelously achieved.” Christian Schmidt, Molecular Cell\u003c\/p\u003e \u003cp\u003e“Chapters address the issues of cancer diagnosis, treatment, and patient care and set the book apart from general molecular biology references….This book is applicable to both graduate and undergraduate students, and in the context of a research laboratory, this book would be an excellent resource as a reference guide for scientists at all levels.” V.Emuss, Institute of Cancer Research, London.\u003c\/p\u003e \u003cp\u003eAlso, from the first edition:\u003c\/p\u003e \u003cp\u003e“Pelengaris, Khan, and the contributing authors are to be applauded. \u003ci\u003eThe Molecular Biology of Cancer\u003c\/i\u003e is a comprehensive and readable presentation of the many faces of cancer from molecular mechanisms to clinical therapies and diagnostics. This book will be welcomed by neophyte students, established scientists in other fields, and curious physicians.” -Dean Felsher, Stanford University\u003c\/p\u003e \u003cp\u003eContributors vii\u003c\/p\u003e \u003cp\u003ePreface to the Second Edition ix\u003c\/p\u003e \u003cp\u003eReviews of the First Edition x\u003c\/p\u003e \u003cp\u003eAcknowledgments and Dedication xi\u003c\/p\u003e \u003cp\u003eAbout the Companion Website xii\u003c\/p\u003e \u003cp\u003eIntroduction 1\u003c\/p\u003e \u003cp\u003e\u003cb\u003e1 Overview of Cancer Biology 3\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael Khan and Stella Pelengaris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 5\u003c\/p\u003e \u003cp\u003eCancer incidence and epidemiology 8\u003c\/p\u003e \u003cp\u003eTowards a definition of cancer 8\u003c\/p\u003e \u003cp\u003eCauses of cancer 16\u003c\/p\u003e \u003cp\u003eCancer is a genetic disease 21\u003c\/p\u003e \u003cp\u003eCancers (and Darwin’s finches) evolve by mutation and natural selection 21\u003c\/p\u003e \u003cp\u003eBlame the parents – inherited single gene defects and susceptibility to cancer 21\u003c\/p\u003e \u003cp\u003eThe cancer “roadmap” – What kinds of genes are epimutated in cancer? 23\u003c\/p\u003e \u003cp\u003eViruses and the beginnings of cancer biology 25\u003c\/p\u003e \u003cp\u003eHens and teeth or bears and woods? The hens have it – cancer is rare 25\u003c\/p\u003e \u003cp\u003eThe barriers to cancer 25\u003c\/p\u003e \u003cp\u003eWhat is the secret of cancer developme “timing” 28\u003c\/p\u003e \u003cp\u003eLocation location location – the cancer environment: nanny or spartan state 28\u003c\/p\u003e \u003cp\u003eCancer goes agricultural 29\u003c\/p\u003e \u003cp\u003eCancer superhighways – blood vessels and lymphatics 31\u003c\/p\u003e \u003cp\u003eOn your bike and turn the lights off before you go 31\u003c\/p\u003e \u003cp\u003eCatching cancer 31\u003c\/p\u003e \u003cp\u003eHammering the hallmarks 32\u003c\/p\u003e \u003cp\u003ePainting a portrait of cancer 33\u003c\/p\u003e \u003cp\u003eThe drugs don’t work 34\u003c\/p\u003e \u003cp\u003eMechanism of origin rather than cell of origin – towards a new functional taxonomy of cancer 35\u003c\/p\u003e \u003cp\u003eIs it worth it? 36\u003c\/p\u003e \u003cp\u003eConclusions and future directions 36\u003c\/p\u003e \u003cp\u003eBibliography 37\u003c\/p\u003e \u003cp\u003eAppendix 1.1 History of cancer 40\u003c\/p\u003e \u003cp\u003e\u003cb\u003e2 The Burden of Cancer 43\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eWilliam P. Steward and Anne L. Thomas\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 43\u003c\/p\u003e \u003cp\u003eLung cancer 45\u003c\/p\u003e \u003cp\u003eBreast cancer 49\u003c\/p\u003e \u003cp\u003eColorectal cancer 53\u003c\/p\u003e \u003cp\u003eCarcinoma of the prostate 56\u003c\/p\u003e \u003cp\u003eRenal carcinoma 57\u003c\/p\u003e \u003cp\u003eSkin cancer 58\u003c\/p\u003e \u003cp\u003eCarcinoma of the cervix 60\u003c\/p\u003e \u003cp\u003eHematological malignancies 60\u003c\/p\u003e \u003cp\u003eConclusions and future directions 63\u003c\/p\u003e \u003cp\u003eOutstanding questions 63\u003c\/p\u003e \u003cp\u003eBibliography 64\u003c\/p\u003e \u003cp\u003eQuestions for student review 66\u003c\/p\u003e \u003cp\u003e\u003cb\u003e3 Nature and Nurture in Oncogenesis 67\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael Khan and Stella Pelengaris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 69\u003c\/p\u003e \u003cp\u003eRisk factors 73\u003c\/p\u003e \u003cp\u003ePreventing cancers 76\u003c\/p\u003e \u003cp\u003eCancer genetics – in depth 78\u003c\/p\u003e \u003cp\u003eCancer genomics 87\u003c\/p\u003e \u003cp\u003eGene–environment interactions 89\u003c\/p\u003e \u003cp\u003eMutations and treatment 89\u003c\/p\u003e \u003cp\u003eChemoprevention of cancer 90\u003c\/p\u003e \u003cp\u003eRisk factors act in combination 90\u003c\/p\u003e \u003cp\u003eEnvironmental causes of cancer 93\u003c\/p\u003e \u003cp\u003eThe clinical staging and histological examination of cancer 101\u003c\/p\u003e \u003cp\u003eScreening and biomarkers 102\u003c\/p\u003e \u003cp\u003eSomatic gene mutations epigenetic alterations and multistage tumorigenesis 105\u003c\/p\u003e \u003cp\u003eConclusions and future directions 107\u003c\/p\u003e \u003cp\u003eOutstanding questions 107\u003c\/p\u003e \u003cp\u003eBibliography 107\u003c\/p\u003e \u003cp\u003eQuestions for student review 109\u003c\/p\u003e \u003cp\u003e\u003cb\u003e4 DNA Replication and the Cell Cycle 111\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStella Pelengaris and Michael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 112\u003c\/p\u003e \u003cp\u003eThe cell cycle – overview 114\u003c\/p\u003e \u003cp\u003ePhases of the cell cycle 120\u003c\/p\u003e \u003cp\u003eThe cell-cycle engine: cyclins and kinases 123\u003c\/p\u003e \u003cp\u003eRegulation by degradation 126\u003c\/p\u003e \u003cp\u003eRegulation by transcription 129\u003c\/p\u003e \u003cp\u003eMicroRNAs and the cell cycle 131\u003c\/p\u003e \u003cp\u003eChromatin 131\u003c\/p\u003e \u003cp\u003eDNA replication and mitosis 131\u003c\/p\u003e \u003cp\u003eCheckpoints – putting breaks on the cell-cycle engine 135\u003c\/p\u003e \u003cp\u003eThe DNA damage response (DDR) 136\u003c\/p\u003e \u003cp\u003eThe checkpoints 136\u003c\/p\u003e \u003cp\u003eCell-cycle entry and its control by extracellular signals 138\u003c\/p\u003e \u003cp\u003eChanges in global gene expression during the cell cycle 139\u003c\/p\u003e \u003cp\u003eCell cycle and cancer 139\u003c\/p\u003e \u003cp\u003eDrugging the cell cycle in cancer therapies 141\u003c\/p\u003e \u003cp\u003eConclusions and future directions 142\u003c\/p\u003e \u003cp\u003eOutstanding questions 143\u003c\/p\u003e \u003cp\u003eBibliography 143\u003c\/p\u003e \u003cp\u003eQuestions for student review 144\u003c\/p\u003e \u003cp\u003e\u003cb\u003e5 Growth Signaling Pathways and the New Era of Targeted Treatment of Cancer 146\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStella Pelengaris and Michael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 147\u003c\/p\u003e \u003cp\u003eGrowth factor regulation of the cell cycle 150\u003c\/p\u003e \u003cp\u003eGrowth homeostasis and tissue repair and regeneration 151\u003c\/p\u003e \u003cp\u003eRegulated and deregulated growth 155\u003c\/p\u003e \u003cp\u003eCellular differentiation 157\u003c\/p\u003e \u003cp\u003eTissue growth and the “angiogenic switch” 158\u003c\/p\u003e \u003cp\u003eCancers and nutrients 158\u003c\/p\u003e \u003cp\u003eGrowth factor signaling pathways 160\u003c\/p\u003e \u003cp\u003eA detailed description of signal transduction pathways and their subversion in cancer 160\u003c\/p\u003e \u003cp\u003eTranslational control and growth 184\u003c\/p\u003e \u003cp\u003eConclusions and future directions 185\u003c\/p\u003e \u003cp\u003eOutstanding questions 185\u003c\/p\u003e \u003cp\u003eBibliography 186\u003c\/p\u003e \u003cp\u003eQuestions for student review 187\u003c\/p\u003e \u003cp\u003e\u003cb\u003e6 Oncogenes 188\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStella Pelengaris and Michael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 189\u003c\/p\u003e \u003cp\u003eThe oncogenes 189\u003c\/p\u003e \u003cp\u003eThe discovery of oncogenes ushers in the new era of the molecular biology of cancer 191\u003c\/p\u003e \u003cp\u003eOverview of oncogenes 191\u003c\/p\u003e \u003cp\u003eTypes of oncogenes 193\u003c\/p\u003e \u003cp\u003eOncogene collaboration – from cell culture to animal models 199\u003c\/p\u003e \u003cp\u003eThe c-MYC oncogene 199\u003c\/p\u003e \u003cp\u003eThe RAS superfamily 213\u003c\/p\u003e \u003cp\u003eSRC – the oldest oncogene 228\u003c\/p\u003e \u003cp\u003eBCR–ABL and the Philadelphia chromosome 232\u003c\/p\u003e \u003cp\u003eThe BCL-2 family 235\u003c\/p\u003e \u003cp\u003eBiologically targeted therapies in cancer and the concept of “oncogene addiction” 235\u003c\/p\u003e \u003cp\u003eConclusions and future directions 235\u003c\/p\u003e \u003cp\u003eOutstanding questions 236\u003c\/p\u003e \u003cp\u003eBibliography 236\u003c\/p\u003e \u003cp\u003eQuestions for student review 238\u003c\/p\u003e \u003cp\u003e\u003cb\u003e7 Tumor Suppressors 239\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMartine F. Roussel\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 239\u003c\/p\u003e \u003cp\u003eThe “two-hits” hypothesis: loss of heterozygosity (loh) 240\u003c\/p\u003e \u003cp\u003eHaploinsufficiency in cancer 240\u003c\/p\u003e \u003cp\u003eEpigenetic events 242\u003c\/p\u003e \u003cp\u003eDefinition of a tumor suppressor 242\u003c\/p\u003e \u003cp\u003eThe retinoblastoma protein family 242\u003c\/p\u003e \u003cp\u003ep53\/TP53 250\u003c\/p\u003e \u003cp\u003eINK4a\/ARF 254\u003c\/p\u003e \u003cp\u003eThe p53 and RB pathways in cancer 257\u003c\/p\u003e \u003cp\u003eSenescence and immortalization: Role of RB and p53 258\u003c\/p\u003e \u003cp\u003eTumor suppressors and the control of cell proliferation 258\u003c\/p\u003e \u003cp\u003eTumor suppressors and control of the DNA damage response and genomic stability 260\u003c\/p\u003e \u003cp\u003eThe microRNAs and tumor suppressors 260\u003c\/p\u003e \u003cp\u003eConclusions and future directions 263\u003c\/p\u003e \u003cp\u003eAcknowledgments 263\u003c\/p\u003e \u003cp\u003eOutstanding questions 264\u003c\/p\u003e \u003cp\u003eBibliography 264\u003c\/p\u003e \u003cp\u003eQuestions for student review 265\u003c\/p\u003e \u003cp\u003e\u003cb\u003e8 Cell Death 266\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStella Pelengaris and Michael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 267\u003c\/p\u003e \u003cp\u003eAn historical perspective 267\u003c\/p\u003e \u003cp\u003eApoptosis in context 267\u003c\/p\u003e \u003cp\u003eApoptosis as a barrier to cancer formation 271\u003c\/p\u003e \u003cp\u003eApoptosis versus necrosis 271\u003c\/p\u003e \u003cp\u003eCell death by necrosis – not just inflammatory 272\u003c\/p\u003e \u003cp\u003eThe pathways to apoptosis 272\u003c\/p\u003e \u003cp\u003eThe apoptosome – “wheel of death” 274\u003c\/p\u003e \u003cp\u003eCaspases – the initiators and executioners of apoptosis 274\u003c\/p\u003e \u003cp\u003eThe IAP family – inhibitors of apoptosis and much more 276\u003c\/p\u003e \u003cp\u003eThe central role of MOMP and its regulators in apoptosis – the BCL-2 family 279\u003c\/p\u003e \u003cp\u003eMitochondrial outer membrane permeabilization (momp) 281\u003c\/p\u003e \u003cp\u003eEndoplasmic reticulum stress 282\u003c\/p\u003e \u003cp\u003eStress-inducible heat shock proteins 282\u003c\/p\u003e \u003cp\u003eTumor suppressor p53 282\u003c\/p\u003e \u003cp\u003eOncogenic stress: MYC-induced apoptosis 283\u003c\/p\u003e \u003cp\u003eAutophagy – a different kind of cell death and survival 287\u003c\/p\u003e \u003cp\u003eCell death in response to cancer therapy 290\u003c\/p\u003e \u003cp\u003eExploiting cell death (and senescence) in cancer control 290\u003c\/p\u003e \u003cp\u003eConclusions and future directions 292\u003c\/p\u003e \u003cp\u003eOutstanding questions 293\u003c\/p\u003e \u003cp\u003eBibliography 293\u003c\/p\u003e \u003cp\u003eQuestions for student review 294\u003c\/p\u003e \u003cp\u003e\u003cb\u003e9 Senescence Telomeres and Cancer Stem Cells 295\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMaria A. Blasco and Michael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 296\u003c\/p\u003e \u003cp\u003eSenescence 298\u003c\/p\u003e \u003cp\u003eConclusions and future directions 310\u003c\/p\u003e \u003cp\u003eOutstanding questions 310\u003c\/p\u003e \u003cp\u003eBibliography 311\u003c\/p\u003e \u003cp\u003eQuestions for student review 312\u003c\/p\u003e \u003cp\u003e\u003cb\u003e10 Genetic Instability Chromosomes and Repair 314\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 316\u003c\/p\u003e \u003cp\u003eTelomere attrition and genomic instability 321\u003c\/p\u003e \u003cp\u003eSensing DNA damage 323\u003c\/p\u003e \u003cp\u003eRepairing DNA damage 325\u003c\/p\u003e \u003cp\u003eCheckpoints 336\u003c\/p\u003e \u003cp\u003eMicrosatellites and minisatellites 343\u003c\/p\u003e \u003cp\u003eChaperones and genomic instability 344\u003c\/p\u003e \u003cp\u003eCancer susceptibility syndromes involving genetic instability 345\u003c\/p\u003e \u003cp\u003eGenomic instability and colon cancer 346\u003c\/p\u003e \u003cp\u003eConclusions and future directions 346\u003c\/p\u003e \u003cp\u003eOutstanding questions 347\u003c\/p\u003e \u003cp\u003eBibliography 347\u003c\/p\u003e \u003cp\u003eQuestions for student review 349\u003c\/p\u003e \u003cp\u003e\u003cb\u003e11 There Is More to Cancer than Genetics: Regulation of Gene and Protein Expression by Epigenetic Factors Small Regulatory RNAs and Protein Stability 350\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eStella Pelengaris and Michael Khan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 351\u003c\/p\u003e \u003cp\u003eThe language of epigenetics 353\u003c\/p\u003e \u003cp\u003eEpigenetics 353\u003c\/p\u003e \u003cp\u003eMethylation of DNA 359\u003c\/p\u003e \u003cp\u003eAcetylation of histones and other posttranslational modifications 360\u003c\/p\u003e \u003cp\u003eEpigenetics and cancer 362\u003c\/p\u003e \u003cp\u003eCIMP and MIN and the “mutator phenotype” 365\u003c\/p\u003e \u003cp\u003eImprinting and loss of imprinting 366\u003c\/p\u003e \u003cp\u003eClinical use of epigenetics 367\u003c\/p\u003e \u003cp\u003eRegulation of translation 368\u003c\/p\u003e \u003cp\u003eNoncoding RNA and RNA interference 369\u003c\/p\u003e \u003cp\u003eTherapeutic and research potential of RNAi 371\u003c\/p\u003e \u003cp\u003eTreatments based on miRNA 373\u003c\/p\u003e \u003cp\u003eRegulating the proteins 373\u003c\/p\u003e \u003cp\u003eTherapeutic inhibition of the proteasome 376\u003c\/p\u003e \u003cp\u003eReceptor degradation 377\u003c\/p\u003e \u003cp\u003eWrestling with protein transit – the role of SUMO and the promyelocytic leukemia (PML) body 377\u003c\/p\u003e \u003cp\u003eConclusions and future directions 380\u003c\/p\u003e \u003cp\u003eOutstanding questions 380\u003c\/p\u003e \u003cp\u003eBibliography 381\u003c\/p\u003e \u003cp\u003eQuestions for student review 382\u003c\/p\u003e \u003cp\u003e\u003cb\u003e12 Cell Adhesion in Cancer 383\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCharles H. Streuli\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 383\u003c\/p\u003e \u003cp\u003eAdhesive interactions with the extracellular matrix 384\u003c\/p\u003e \u003cp\u003eCell–cell interactions 393\u003c\/p\u003e \u003cp\u003eCritical steps in the dissemination of metastases 395\u003c\/p\u003e \u003cp\u003eE-cadherin downregulation in cancer leads to migration 399\u003c\/p\u003e \u003cp\u003eEpithelial–mesenchymal transitions 401\u003c\/p\u003e \u003cp\u003eIntegrins metalloproteinases and cell invasion 402\u003c\/p\u003e \u003cp\u003eSurvival in an inappropriate environment 404\u003c\/p\u003e \u003cp\u003eConclusions 406\u003c\/p\u003e \u003cp\u003eOutstanding questions 406\u003c\/p\u003e \u003cp\u003eBibliography 407\u003c\/p\u003e \u003cp\u003eQuestions for student review 409\u003c\/p\u003e \u003cp\u003e\u003cb\u003e13 Tumor Immunity and Immunotherapy 410\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eCassian Yee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 410\u003c\/p\u003e \u003cp\u003eEndogenous immune response 411\u003c\/p\u003e \u003cp\u003eEffector cells in tumor immunity 413\u003c\/p\u003e \u003cp\u003eTumor antigens 417\u003c\/p\u003e \u003cp\u003eAntigen-specific therapy of cancer 420\u003c\/p\u003e \u003cp\u003eClinical trials in vaccine therapy 422\u003c\/p\u003e \u003cp\u003eCytokine therapy of cancer 423\u003c\/p\u003e \u003cp\u003eTumor immune evasion 424\u003c\/p\u003e \u003cp\u003eClinical trials in immunomodulatory therapy 425\u003c\/p\u003e \u003cp\u003eConclusions 425\u003c\/p\u003e \u003cp\u003eBibliography 426\u003c\/p\u003e \u003cp\u003eQuestions for student review 427\u003c\/p\u003e \u003cp\u003e\u003cb\u003e14 Tumor Angiogenesis 429\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eChristiana Ruhrberg\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 429\u003c\/p\u003e \u003cp\u003eGeneral principles of new vessel growth 430\u003c\/p\u003e \u003cp\u003ePathological neovascularization: tumor vessels 430\u003c\/p\u003e \u003cp\u003eBasic concepts in tumor angiogenesis: the angiogenic switch 432\u003c\/p\u003e \u003cp\u003eVascular growth and differentiation factors: stimulators of the angiogenic switch 432\u003c\/p\u003e \u003cp\u003eRole of inhibitors in angiogenesis 436\u003c\/p\u003e \u003cp\u003eClinical outcomes and future directions 436\u003c\/p\u003e \u003cp\u003eAcknowledgments 437\u003c\/p\u003e \u003cp\u003eBibliography 437\u003c\/p\u003e \u003cp\u003eQuestions for student review 437\u003c\/p\u003e \u003cp\u003e\u003cb\u003e15 Cancer Chemistry: Designing New Drugs for Cancer Treatment 438\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAna M. Pizarro and Peter J. Sadler\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 439\u003c\/p\u003e \u003cp\u003eHistorical perspective 439\u003c\/p\u003e \u003cp\u003eThe drug discovery process and preclinical development of a drug 442\u003c\/p\u003e \u003cp\u003eQuestions remaining 457\u003c\/p\u003e \u003cp\u003eConclusions and future directions 457\u003c\/p\u003e \u003cp\u003eBibliography 458\u003c\/p\u003e \u003cp\u003eQuestions for student review 459\u003c\/p\u003e \u003cp\u003e\u003cb\u003e16 Biologically Targeted Agents from Bench to Bedside 461\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eMichael Khan Peter Sadler Ana M. Pizarro and Stella Pelengaris\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 463\u003c\/p\u003e \u003cp\u003eTargeted therapies 465\u003c\/p\u003e \u003cp\u003eCancer cell heterogeneity 466\u003c\/p\u003e \u003cp\u003eFinding the molecular targets 468\u003c\/p\u003e \u003cp\u003eTumor regression in mice by inactivating single oncogenes 468\u003c\/p\u003e \u003cp\u003eTargeted cancer therapies 473\u003c\/p\u003e \u003cp\u003eTargeting oncogenes to treat cancer? 473\u003c\/p\u003e \u003cp\u003eThe concept of synthetic lethality and collateral vulnerability 475\u003c\/p\u003e \u003cp\u003eClinical progress in biological and molecular targeted therapies 476\u003c\/p\u003e \u003cp\u003eMolecular targeted drugs – an inventory 479\u003c\/p\u003e \u003cp\u003eDNA damage responses 490\u003c\/p\u003e \u003cp\u003eTranscription factors 491\u003c\/p\u003e \u003cp\u003eTargeting epigenetic regulation of gene expression 492\u003c\/p\u003e \u003cp\u003eHitting the extrinsic support network and preventing spread 493\u003c\/p\u003e \u003cp\u003eGene therapy antisense and siRNA 495\u003c\/p\u003e \u003cp\u003eResistance to targeted therapies – intrinsic resistance and emergence of secondary pathways and tumor escape 497\u003c\/p\u003e \u003cp\u003eNegative feedback loops and failure of targeted therapies 500\u003c\/p\u003e \u003cp\u003eBiomarkers to identify optimal treatments and tailored therapies 501\u003c\/p\u003e \u003cp\u003ePharmacogenetics and pharmacogenomics 505\u003c\/p\u003e \u003cp\u003eClinical trials in cancer 506\u003c\/p\u003e \u003cp\u003eConclusions and future directions 506\u003c\/p\u003e \u003cp\u003eBibliography 507\u003c\/p\u003e \u003cp\u003eQuestions for student review 508\u003c\/p\u003e \u003cp\u003e\u003cb\u003e17 The Diagnosis of Cancer 509\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAnne L. Thomas Bruno Morgan and William P. Steward\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 509\u003c\/p\u003e \u003cp\u003eClinical manifestations 510\u003c\/p\u003e \u003cp\u003eInvestigations in oncological practice 511\u003c\/p\u003e \u003cp\u003eNon-invasive imaging techniques 516\u003c\/p\u003e \u003cp\u003eFuture novel uses of imaging 521\u003c\/p\u003e \u003cp\u003eProteomics and microarrays 523\u003c\/p\u003e \u003cp\u003eCirculating tumor cells 523\u003c\/p\u003e \u003cp\u003eDisease staging 523\u003c\/p\u003e \u003cp\u003eConclusions and future directions 524\u003c\/p\u003e \u003cp\u003eBibliography 524\u003c\/p\u003e \u003cp\u003eQuestions for student review 525\u003c\/p\u003e \u003cp\u003e\u003cb\u003e18 Treatment of Cancer: Chemotherapy and Radiotherapy 526\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eAnne L. Thomas J.P. Sage and William P. Steward\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 526\u003c\/p\u003e \u003cp\u003eRadiotherapy physics 526\u003c\/p\u003e \u003cp\u003eRadiobiology 527\u003c\/p\u003e \u003cp\u003eTreatment planning 528\u003c\/p\u003e \u003cp\u003eRecent advances 529\u003c\/p\u003e \u003cp\u003eChemoradiation 530\u003c\/p\u003e \u003cp\u003eConclusion 540\u003c\/p\u003e \u003cp\u003eBibliography 542\u003c\/p\u003e \u003cp\u003eQuestions for student review 543\u003c\/p\u003e \u003cp\u003e\u003cb\u003e19 Caring for the Cancer Patient 544\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eNicky Rudd and Esther Waterhouse\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 544\u003c\/p\u003e \u003cp\u003eKey concepts 544\u003c\/p\u003e \u003cp\u003eCommunication with the cancer patient 544\u003c\/p\u003e \u003cp\u003eWhen is palliative care appropriate for cancer patients? 545\u003c\/p\u003e \u003cp\u003ePalliative care assessment 545\u003c\/p\u003e \u003cp\u003eSymptom control 545\u003c\/p\u003e \u003cp\u003eRespiratory symptoms 547\u003c\/p\u003e \u003cp\u003eNausea and vomiting 547\u003c\/p\u003e \u003cp\u003eBowel obstruction 548\u003c\/p\u003e \u003cp\u003eConstipation 549\u003c\/p\u003e \u003cp\u003eFatigue 549\u003c\/p\u003e \u003cp\u003eCachexia and anorexia 549\u003c\/p\u003e \u003cp\u003ePsychological problems 549\u003c\/p\u003e \u003cp\u003eThe dying patient 550\u003c\/p\u003e \u003cp\u003eSupportive care 550\u003c\/p\u003e \u003cp\u003eAn example of the care of a cancer patient 551\u003c\/p\u003e \u003cp\u003eQuestions remaining 551\u003c\/p\u003e \u003cp\u003eConclusions and future directions 551\u003c\/p\u003e \u003cp\u003eUnderlying problems 551\u003c\/p\u003e \u003cp\u003eComment 551\u003c\/p\u003e \u003cp\u003eUnderlying problems 552\u003c\/p\u003e \u003cp\u003eBibliography 552\u003c\/p\u003e \u003cp\u003eQuestions for student review 553\u003c\/p\u003e \u003cp\u003e\u003cb\u003e20 Systems Biology of Cancer 554\u003cbr\u003e \u003c\/b\u003e\u003ci\u003eWalter Schubert Norbert C.J. de Wit and Peter Walden\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIntroduction 556\u003c\/p\u003e \u003cp\u003eInformation flow in cells 556\u003c\/p\u003e \u003cp\u003eModel organisms and cancer models 557\u003c\/p\u003e \u003cp\u003eArray-based technologies: genomics epigenomics and transcriptomics 559\u003c\/p\u003e \u003cp\u003eSNPs the HapMap and the identification of cancer genes 559\u003c\/p\u003e \u003cp\u003eCancer mRNA expression analysis 562\u003c\/p\u003e \u003cp\u003eCGH arrays CpG island microarrays and ChIP-on-Chip 564\u003c\/p\u003e \u003cp\u003eNext-generation sequencing 564\u003c\/p\u003e \u003cp\u003eProteomics 566\u003c\/p\u003e \u003cp\u003ePosttranslational modifications 567\u003c\/p\u003e \u003cp\u003eProtein complexes and cellular networks 569\u003c\/p\u003e \u003cp\u003eClinical applications of proteomics 570\u003c\/p\u003e \u003cp\u003eToponomics: investigating the protein network code of cells and tissues 571\u003c\/p\u003e \u003cp\u003eProcessing the images from the cyclical imaging procedures 571\u003c\/p\u003e \u003cp\u003eStructure code and semantics of the toponome: a high-dimensional combinatorial problem 573\u003c\/p\u003e \u003cp\u003eDetecting a cell surface protein network code: lessons from a tumor cell 575\u003c\/p\u003e \u003cp\u003eThe molecular face of cells in diseases 576\u003c\/p\u003e \u003cp\u003eIndividualized medicine and tailored therapies 576\u003c\/p\u003e \u003cp\u003eDiscussion and conclusion 579\u003c\/p\u003e \u003cp\u003eBibliography 579\u003c\/p\u003e \u003cp\u003eInternet resources 581\u003c\/p\u003e \u003cp\u003eQuestions for student review 582\u003c\/p\u003e \u003cp\u003eAppendix 20.1 Techniques for the generation of genetically altered mouse models of cancer 582\u003c\/p\u003e \u003cp\u003eGlossary 585\u003c\/p\u003e \u003cp\u003eAnswers to Questions 597\u003c\/p\u003e \u003cp\u003eIndex 603\u003c\/p\u003e  \u003cp\u003e“An excellent didactic technical production. For medical students, trainees, cancer biologists, oncologists, pharmacologists and endocrinologists. Cancer remains a menace in modern times.”  (\u003ci\u003ePediatric Endocrinology Reviews\u003c\/i\u003e, 1 September 2013)\u003c\/p\u003e \u003cp\u003e“This book will be invaluable for nursing and medical students, establishing a basic understanding and progressing to more complex issues.  The end-of-chapter review questions are great preparation for exams.”  \u003ci\u003e(Nursing Standard\u003c\/i\u003e, 1 September 2013\u003c\/p\u003e \u003cp\u003e\u003cb\u003eStella Pelengaris\u003c\/b\u003e Ph.D is Director of Pharmalogos and previous Researcher at the Imperial Cancer Research Fund, and Senior Research Fellow at the University of Warwick and Warwick Medical School.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMike Khan\u003c\/b\u003e Ph.D FRCP is Associate Professor of Medicine at University Hospitals of Coventry and Warwickshire and previous Head of Molecular Medicine at the University of Warwick.\u003c\/p\u003e  \u003cp\u003eNewly revised and updated for its second edition, this comprehensive text provides a detailed overview of the molecular mechanisms underpinning the development of cancer and its treatment. Written by an international panel of researchers, specialists and practitioners in the field, the text discusses all aspects of cancer biology from the molecular causes, development and diagnosis through to the treatment of cancer patients.\u003c\/p\u003e \u003cul\u003e \u003cli\u003eNew coverage on how cancer drugs are actually used in specific cancer patients, and how therapies are developed and tested\u003c\/li\u003e \u003cli\u003e Covers both traditional areas of study and areas of controversy and emerging importance, highlighting future directions for research\u003c\/li\u003e \u003cli\u003e Features up-to-date coverage of recent studies and discoveries, as well as a solid grounding in the key concepts in the field\u003c\/li\u003e \u003cli\u003eHighlights the direct links between cancer research and clinical applications\u003c\/li\u003e \u003cli\u003eEach chapter includes key points, chapter summaries, text boxes, and topical references for added comprehension and review\u003c\/li\u003e \u003cli\u003eSupported by a dedicated website at [INSERT NEW URL]\u003c\/li\u003e \u003cli\u003eAn excellent text for upper-level courses in the biology of cancer, for medical students and qualified practitioners preparing for higher exams, and for researchers and teachers in the field\u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003e\u003cb\u003eStella Pelengaris\u003c\/b\u003e Ph.D is Director of Pharmalogos and previous Researcher at the Imperial Cancer Research Fund, and Senior Research Fellow at the University of Warwick and Warwick Medical School.\u003c\/p\u003e \u003cp\u003e\u003cb\u003eMike Khan\u003c\/b\u003e Ph.D FRCP is Associate Professor of Medicine at University Hospitals of Coventry and Warwickshire and previous Head of Molecular Medicine at the University of Warwick.\u003cbr\u003e \u003cbr\u003e Reviews of the first edition:\u003c\/p\u003e \u003cp\u003e\"A capturing, comprehensive, clearly written and absolutely accurate introduction into cancer biology…This book deserves great praise for the readable presentation of this complex field…..the true synthesis of bench and bedside approaches is marvelously achieved….\"                         - \u003ci\u003eMolecular Cancer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e“Chapters address the issues of cancer diagnosis, treatment and patient care and set the book apart from general molecular biology reference….This book is applicable to both graduate and undergraduate students, and in the context of a research laboratory, this book would be an excellent resource as a reference guide for scientists at all levels.”                    - V. Emuss, Institute of Cancer Research, London\u003c\/p\u003e \u003cp\u003e \u003c\/p\u003e","brand":"Wiley-Blackwell","offers":[{"title":"Default Title","offer_id":47990290022629,"sku":"NP9781118008812","price":119.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9781118008812.jpg?v=1761787220","url":"https:\/\/k12savings.com\/products\/the-molecular-biology-of-cancer-isbn-9781118008812","provider":"K12savings","version":"1.0","type":"link"}